We propose here to explore systematically the association between drug-metabolizing enzymes
activity assessed by a phenotypical approach and antidepressant plasma concentration,
efficacy and tolerance in the clinical setting. During one year, patients receiving
antidepressant will be included in tis prospective clinical, naturalistic and descriptive
pilot study.